Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia

Psychotherapy and Psychosomatics

Volumn 76, Issue 4, 2007, Pages 213-218

  Yury, Craig A ^a   Fisher, Jane E ^a  

^a UNIVERSITY OF NEVADA   (United States)

Author keywords

Antipsychotics; Behavioural problems; Dementia; Meta analysis

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

BEHAVIOR DISORDER; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEMENTIA; DRUG EFFICACY; HUMAN; MEDLINE; META ANALYSIS; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CONTROLLED CLINICAL TRIALS; DEMENTIA; DIBENZOTHIAZEPINES; FOLLOW-UP STUDIES; HUMANS; MENTAL DISORDERS; RISPERIDONE;

EID: 34250658026     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101499     Document Type: Review

References (37)

1. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC: Mental and behavioral disturbances in dementia: findings from the Cache County Study on memory in aging. Am J Psychiatry 2000;157:708-714.
2. Parnetti L, Amici S, Lanari A, Gallai V: Pharmacological treatment of non-cognitive disturbances in dementia disorders. Mech Ageing Dev 2001;122:2063-2069.
3. Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A: Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996;153:1438-1443.
4. Lyketsos CG, Steele C, Galik E, Rosenblatt A, Steinberg M, Warren A, Sheppard JM: Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry 1999;156:66-71.
5. Devanand DP, Jacobs DM, Tang MX, Del Castillo-Castaneda C, Sano M, Marder K, Bell K, Bylsma FW, Brandt J, Albert M, Stern Y: The course of psychopathologic features in mild to moderate Alzheimer's disease. Arch Gen Psychiatry 1997;54:257-263.
6. Verma SD, Davidoff DA, Kambhampati KK: Management of the agitated elderly patient in the nursing home: the role of the atypical antipsychotics. J Clin Psychiatry 1998;59:50-55.
7. Sweet RA, Pollock BG: Neuroleptics in the elderly: guidelines for monitoring. Harv Rev Psychiatry 1995;2:327-335.
8. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA: Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med 2005;353:2335-2341.
9. Colenda CC, Mickus MA, Marcus SC, Tanielian TL, Pincus HA: Comparison of adult and geriatric psychiatric practice patterns: findings from the American Psychiatric Association's Practice Research Network. Am J Geriatr Psychiatry 2002;10:609-617.
10. Giron MS, Forsell Y, Bernsten C, Thorslun M, Winblad B, Fastbom J: Psychotropic drug use in elderly people with and without dementia. Int J Geriatr Psychiatry 2001;16:900-906.
11. Briesacher BA, Limcangco R, Simoni-Wastila L, et al: The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 2005;165:1280-1285.
12. Hien LT, Cumming RC, Cameron ID, Chen JS, Lord SR, March LM, Schwarz J, Le Couteur DG, Sambrook PN: Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005;53:1290-1295.
13. Stoppe G, Staedt J: Psychopharmacology of behavioural disorders in patients with dementia. Gerontol Geriatr 1999;32:153-158.
14. Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293:596-607.
15. Leipzig R, Cummings RG, Tinetti ME: Drugs and falls in older people: a systematic review and meta-analysis. 1. Psychotropic drugs. J Am Geriatr Soc 1999;47:30-39.
16. Maguire GA: Impact of antipsychotics on geriatric patients: efficacy, dosing, and compliance. Prim Care Companion J Clin Psychiatry 2000;2:165-172.
17. Food and Drug Administration: FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/olanzapine-HCP.htm (accessed April 12, 2006).
18. Thalheimer W, Cook S: How to calculate effect sizes from published research articles: a simplified methodology. Available at: http://work-learning. com/effect_sizes.htm (accessed January 20, 2005).
19. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jacoby R: Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised doubleblind placebo-controlled trial. BMJ 2005;330:874-897.
20. Brodaty H, Ames D, Snowdon H, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F: A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64:134-143.
21. Clark WS, Street JS, Feldman PD, Breieret A: The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry 2001;62:34-40.
22. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, Lawloe BA: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946-955.
23. De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman, DL, Breier A: Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:115-126.
24. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107-115.
25. Street JS, Clark S, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Fledman PD, Tollefson GD, Breier A: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000;57:968-976.
26. Chan W, Lam LC, Choy CN, Leung VP, Li S, Chiu HF: A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001;16:1156-1162.
27. Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF: A doubleblind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 2003;64:726-730.
28. Fujikawa T, Takahashi T, Kinoshita A, Kajiyama H, Kurata A, Yamashita H, Yamawaki S: Quetiapine treatment for behavioral and psychological symptoms of patients with senile dementia of Alzheimer type. Neuropsychobiology 2004;49:201-204.
29. Street JS, Clark WS, Kadam DL, Mitn SJ, Juliar BE, Feldman PD, Breier A: Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry 2001;16:S62-S70.
30. Yoon J, Kim J, Lee H, Shin I, Choi S: Risperidone use in Korean patients with Alzheimer's disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living. Hum Psychopharmacol 2003;18:627-633.
31. Lavertsky H, Sultzer D: A structured trial of risperidone for the treatment of agitation in dementia. Am J Geriatr Psychiatry 1998;6:127-135.
32. Rains JC, Penzien DB: Behavioral research and the double-blind placebo-controlled methodology: challenges in applying the biomedical standard to behavioral headache research. Headache 2005;45:479-486.
33. Cohen J: Statistical Power Analysis for the Behavioural Sciences, ed 2. Hillsdale, Erlbaum, 1988.
34. Jacobson NS, Traux P: Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clinical Psychol 2001;59:12-19.
35. Fava GA: The intellectual crisis of psychiatric research. Psychother Psychosom 2006;75:202-208.
36. Rosenthal R: The file drawer problem and tolerance for null results. Psychol Bull 1979;86:638-641.
37. Sensky T: The effectiveness of cognitive therapy for schizophrenia: what can we learn from the meta-analyses? Psychother Psychosom 2005;75:131-135.